| abstract |
1. The compound of formula I! ! and its pharmaceutically acceptable salts, where! A represents O, C (= O), S, SO, or SO2; ! G represents N or C-CN; ! B is a fused 6 membered aryl ring or a fused 5-6 membered heteroaryl ring; ! E represents! ,! ,, and! X represents N or CH; ! D1, D2 and D3 are independently N or CR19; ! D4 and D5 are independently N or CR19 and D6 is O, S or NR20, where at least one of D4 and D5 cannot be CR19; ! D7, D8, D9 and D10 are independently N or CR19, where at least one of D7, D8, D9 and D10 is N; ! R1 represents H or alkyl; ! each R2 is independently halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, -SR18, -OR15, -C (O) R15, -C (O) OR15, -NR14C (O) OR18, -OC (O) R15, -NR14SO2R18, -SO2NR15R14, -NR14C (O) R15, -C (O) NR15R14, -NR15C (O) NR15R14, -NR13C (NCN) NR15R14, -NR15R14, alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, cycloalkylalkyl, -S (O) p (alkyl), S (O) p (CR13R14) q-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, saturated or partially unsaturated heterocyclyl, heterocyclylalkyl, (CR13R14) q-aryl, -NR15 (CR13R14) q-aryl, -O (CR13R14) q-heteroaryl, -NR13 (CR13R14) q-heteroaryl,! —O (CR13R14) q-heterocyclyl or —NR15 (CR13R14) q-heterocyclyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl moieties are optionally selected from several other or independently selected groups oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, - NR13SO2R18, -SO2NR15R13, -C (O) R15, -C (O) OR15, -OC (O) R15, -NR13C (O) R18, -NR13C (O) R15, -C (O) NR15R13, -NR15R13, -NR |